Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.

Autor: Tamiya Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan., Matsumoto S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: shmatsum@east.ncc.go.jp., Zenke Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Ikeda T; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Shibata Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kato T; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan., Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Nakamura A; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan., Furuya N; Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan., Miyamoto S; Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan., Kuyama S; Department of Respiratory Medicine, Iwakuni Clinical Center, Iwakuni, Japan., Nomura S; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Ikeno T; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan., Udagawa H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Sugiyama E; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Nosaki K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Izumi H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Sakai T; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Hashimoto N; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan., Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Jazyk: angličtina
Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2023 Feb; Vol. 176, pp. 103-111. Date of Electronic Publication: 2022 Dec 31.
DOI: 10.1016/j.lungcan.2022.12.019
Abstrakt: Introduction: KRAS G12C is an oncogenic driver mutation, accounting for approximately 14% of Caucasian patients with non-small cell lung cancer (NSCLC). Recently, several KRAS G12C-targeted drugs have been developed; however, the clinico-genomic characteristics of NSCLC patients with KRAS G12C remain unclear.
Materials and Methods: Based on the large-scale prospective lung cancer genomic screening project (LC-SCRUM-Asia) database, the clinico-genomic characteristics and therapeutic outcomes of NSCLC patients with KRAS G12C were evaluated.
Results: From March 2015 to March 2021, 10,023 NSCLC patients were enrolled in LC-SCRUM-Asia. KRAS mutations were detected in 1258 patients (14 %), including G12C in 376 (4.0 %), G12D in 289 (3.1 %) and G12V in 251 (2.7 %). The proportions of males and smokers were higher in patients with KRAS G12C than in those with KRAS non-G12C mutations (males: 73 % vs 63 %, p < 0.001; smokers: 89 % vs 76 %, p < 0.001). KRAS G12C-positive tumors showed a higher tumor mutation burden (TMB) (mean, 8.1 mut/Mb, p < 0.001) and a higher percentage of tumors with programmed cell death ligand-1 (PD-L1) expression ≥50 % (52 %, p = 0.08). The overall survival in patients with KRAS G12C (median, 24.6 months) was not different between patients with other mutation subtypes (G12V: 18.2 months, p = 0.23; G12D: 20.6 months, p = 0.65; other KRAS mutations: 18.3 months, p = 0.20). Among KRAS-mutated patients who received immune checkpoint inhibitors (ICIs), the progression-free survival in G12C-positive patients (median, 3.4 months) was similar to that in G12V-positive patients (4.2 months, p = 0.90), but significantly longer than that in G12D- (2.0 months, p = 0.02) and other KRAS mutation-positive patients (2.5 months, p = 0.02).
Conclusions: The frequencies of KRAS G12C were lower in Asian than in Caucasian NSCLC patients. Among the KRAS-mutated NSCLC patients, G12C-positive tumors showed increased immunogenicity, such as high TMB and high PD-L1 expression, and potential sensitivity to ICIs.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: